News & Updates
Showing Pharmacy articles
Showing
Show Multimedia Only

Osimertinib linked to cardiac events in NSCLC patients
26 Nov 2025
byStephen Padilla
Patients with non-small cell lung cancer (NSCLC) treated with osimertinib have a higher risk of QT prolongation, reduced ejection fraction, and high-grade cardiac failure than those who received placebo or other standard therapies, reports a study.








